PharmaEssentia will spend $46 million to build a new manufacturing facility in Puerto Rico. The move forms part of the ...

After ending 2025 with a strong fourth quarter, AstraZeneca management has doubled down on its ambitious “$80 billion by 2030 ...

As the U.S. backpedals on its mRNA investment, Mexico is embracing the technology through a new manufacturing pact with ...

A batch of untitled letters posted on the FDA’s database in recent days takes aim at what the agency has termed “false or misleading” drug ads from the likes of Novo Nordisk, argenx and Sobi. | A ...

With pressure piling on for CSL, the Australian vaccine and plasma specialist has elected to part ways with its CEO on the ...

Breast cancer drug Kisqali outperformed its 2025 sales target by 9%, while a portfolio of recent launches that includes radioligand therapy Pluvicto, kidney disease drugs Fabhalta and Vanrafia, and ...

Hims & Hers caused a firestorm last week when it revealed that it planned to launch a knockoff version of Novo Nordisk's new ...

With Incyte losing patent protection for blood cancer standout Jakafi in late 2028, the Delaware-based company will have to rely more on its topical cream Opzelura. | With Incyte set to lose patent ...

Amid the fast-moving rollout of the Wegovy pill, Novo Nordisk has taken to advertising’s biggest stage to help get the word ...

With online health and wellness company Hims & Hers opening a new front in the GLP-1 compounding showdown Thursday, the ...

After a brief delay last month, another piece of the Trump administration’s healthcare policy has fallen into place. | ...

With an oversubscribed trading debut now in the books, Veradermics—developing an oral version of the molecule behind ...